Patients with lung adenocarcinoma (LUAD) harboring EGFR mutations other than exon 19 deletions (19del) and L858R had received insufficient attention, and their treatment options remained limited with suboptimal outcomes. The gene discussed is EGFR; the disease is lung adenocarcinoma.